Max A. Milbury

CIK: 0001927056

Transaction Breakdown

Open Market Buys (P)1 (20.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PMN

ProMIS Neurosciences Inc.

Discretionary Trading P&L

Holdings

Transaction History (5 total)

PMN
ProMIS Neurosciences Inc.
May 20, 2026
Award(A)
Option (right to buy)
Direct
18.2K shares-
PMN
ProMIS Neurosciences Inc.
Feb 3, 2026
Award(A)
Direct
6.6K shares at avg. $12.13$80K
PMN
ProMIS Neurosciences Inc.
Oct 3, 2025
Purchase(P)
Direct
30.4K shares at avg. $0.49$15K
PMN
ProMIS Neurosciences Inc.
Sep 22, 2025
Award(A)
Option (right to buy)
Direct
60K shares-
PMN
ProMIS Neurosciences Inc.
Nov 18, 2024
Award(A)
Option (right to buy)
Direct
70K shares-

		Type	Shares	Price		Ownership
May 20, 2026	PMN ProMIS Neurosciences Inc.	Award(A) Option (right to buy)	18,167	-	-	Direct
Feb 3, 2026	PMN ProMIS Neurosciences Inc.	Award(A)	6,595	$12.13	$79,997	Direct
Oct 3, 2025	PMN ProMIS Neurosciences Inc.	Purchase(P)	30,392	$0.49	$14,929	Direct
Sep 22, 2025	PMN ProMIS Neurosciences Inc.	Award(A) Option (right to buy)	60,000	-	-	Direct
Nov 18, 2024	PMN ProMIS Neurosciences Inc.	Award(A) Option (right to buy)	70,000	-	-	Direct

1-5 of 5 transactions

About Milbury Max A.

Milbury Max A. (SEC CIK 0001927056) files insider reports with the SEC as ProMIS Neurosciences Inc. (PMN).

Signal8 holds 5 ownership filings by Milbury Max A., all Form 4s, filed between Nov 20, 2024 and May 22, 2026. Those filings report 5 transactions, from Nov 18, 2024 to May 20, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Milbury Max A.'s filings is in TORONTO, A6.

Recent filings by Milbury Max A.

May 20, 2026: Grant or award of PMN derivative securities (Form 4, code A).
Feb 3, 2026: Grant or award of PMN shares (Form 4, code A).
Oct 3, 2025: Open-market purchase of PMN shares (Form 4, code P).
Sep 22, 2025: Grant or award of PMN derivative securities (Form 4, code A).
Nov 18, 2024: Grant or award of PMN derivative securities (Form 4, code A).

Other insiders filing for ProMIS Neurosciences Inc. (PMN)

Williams Eugene, Director
Cashman Neil, Chief Scientific Officer
Rubino Ivana, Chief Commercial Officer
Kaplan Johanne, Chief Development Officer
WYMAN WILLIAM W, Director
Warma Neil K, Chief Executive Officer

How to read Form 4 transaction codes